

Surrey & North West Sussex Area Prescribing Committee (APC)

Policy Statement	Methylphenidate modified release – Preferred brands
Policy No:	APC 488- 2020
Date of Issue	March 2020
Review Date:	<p><i>March 2023</i></p> <p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal. The recommendation made by the APC will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations:</p> <p>The Area Prescribing Committee recommends branded prescribing of methylphenidate for treating attention deficit hyperactivity disorder in adults (off label) and children over 6 years of age in line with guidance from the NHS Specialist Pharmacy Service</p> <p>The preferred brands are Delmosart & Xenidate XL and they will be considered AMBER shared care on the traffic light system.</p> <p>Other brands Matoride XL, Xaggitin XL, Concerta® XL, Equasym XL® & Medikinet XL® will not be BLACK listed on the traffic light system but it is anticipated that these brands will not be initiated by Surrey & Borders Partnership NHS Foundation Trust moving forwards.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> • Bioequivalence of Delmosart compared to Concerta® XL. • Local prescribing behaviour – link to South West London 	
Date taken to Area Prescribing Committee	4 th March 2020
Agreed by APC members	13 th March 2020

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG